Baxter Recalls Clindamycin Phosphate Injection Due to CGMP Deviations
Baxter Healthcare is voluntarily recalling Clindamycin Phosphate Injection due to Current Good Manufacturing Practice (CGMP) deviations. The affected product was distributed in the US, Puerto Rico, and Chile.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II and is voluntary due to CGMP deviations. The source text does not report any illnesses, injuries, or hospitalizations, and the hazard is theoretical, fitting the criteria for a moderate severity score.
Plain-English summary
Baxter Healthcare Corporation is voluntarily recalling Clindamycin Phosphate in 0.9% Sodium Chloride Injection, 600 mg per 50 mL (12 mg/mL), 50 mL Single-Dose GALAXY Container. The recall is initiated due to Current Good Manufacturing Practice (CGMP) deviations. The specific lot affected is Lot # NC193689 with an expiration date of 10/16/2027.
The product was distributed nationwide in the United States, as well as in Puerto Rico and Chile. The recall was initiated on August 6, 2026, and the FDA classified it as Class II on August 28, 2026. The recall status is ongoing.
Healthcare providers and consumers should check their inventory for the specific lot number and expiration date listed above. If the product is found, it should be returned to the distributor or manufacturer according to standard recall procedures. No specific adverse health events are reported in the source text.
The recalled product
- Product
- CLINDAMYCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE)
- Brand
- CLINDAMYCIN PHOSPHATE
- Manufacturer
- Baxter Healthcare Corporation
- Category
- Drug — Antibiotic Injection
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # NC193689
- Exp Date: 10/16/2027.
Distribution
Related recalls
Same brand · CLINDAMYCIN PHOSPHATE
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateClindamycin topical solution recalled after failing impurity and assay specifications
FDA (Drugs) · 2026-01-21
Same manufacturer · Baxter Healthcare Corporation
See all →- HighBaxter Recalls Vancomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateBaxter Recalls Pantoprazole Sodium Infusion Bags Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Novum IQ Syringe Pump Recalled for Software Infusion Issue
FDA (Devices) · 2026-09-09
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vancomycin Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls CARDENE IV Nicardipine Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateLexia LLC Recalls Broadway Joe's Pain Cream Due to CGMP Deviations
FDA (Drugs) · 2026-09-09